CAM
ANIP icon

Capstone Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Capstone Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3,770
Closed -$229K – 1607
2016
Q4 		$229K Buy
+3,770
New +$231K 0.01% 1494
2015
Q2 		– Sell
-3,780
Closed -$236K – 1611
2015
Q1 		$236K Buy
+3,780
New +$230K 0.01% 1509

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Capstone Asset Management's ANIP Position: Q1 2017 in Review

Capstone Asset Management sold out of ANI Pharmaceuticals (ANIP) in Q1 2017, closing a stake of 3,770 shares — an estimated $229K sold.

Capstone Asset Management first reported a position in ANIP in Q1 2015 and held it in 2 quarters. The position peaked at $236K in Q1 2015. 158 funds tracked by Wall St. Rank hold ANIP as of Q1 2017.

  • Capstone Asset Management reported no remaining ANI Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Capstone Asset Management sold 3,770 ANI Pharmaceuticals shares in Q1 2017, an estimated $229K.
  • Capstone Asset Management first reported a position in ANI Pharmaceuticals in Q1 2015 and held it in 2 quarters.
  • Capstone Asset Management's ANI Pharmaceuticals position peaked at $236K in Q1 2015.
  • 158 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2017.

Based on Capstone Asset Management's 13F filing for Q1 2017, filed 12 Apr 2017.